The Motley Fool··Prosper Junior BakinyCRISPR Therapeutics Eyes Major Year With Pipeline Catalysts Ahead
CRISPR Therapeutics faces pivotal 2024 with multiple clinical trial catalysts, including phase 2 and phase 1 data expected to drive stock movement amid elevated biotech volatility.
VRTXCRSPCRISPR gene editingCASGEVY approval